dalotuzumab + exemestane + ridaforolimus

This is a combination therapy consisting of three agents: dalotuzumab, exemestane, and ridaforolimus. Dalotuzumab is a humanized monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF-1R), which inhibits IGF-1-mediated cell signaling and can induce antibody-dependent cellular cytotoxicity. Exemestane is an oral steroidal aromatase inhibitor that suppresses estrogen synthesis, used in hormone receptor-positive breast cancer. Ridaforolimus is an oral small molecule inhibitor of mammalian target of rapamycin (mTOR), blocking a key pathway involved in cell growth and proliferation. The combination was investigated in phase II clinical trials for postmenopausal women with advanced or metastatic estrogen receptor-positive, high-proliferation breast cancer that had progressed after non-steroidal aromatase inhibitors. The rationale was to simultaneously inhibit the IGF-1R pathway (dalotuzumab), mTOR pathway (ridaforolimus), and estrogen production (exemestane) to overcome resistance mechanisms in hormone-receptor positive breast cancer. Clinical studies found that this triplet regimen did not improve progression-free survival compared to doublet therapy with ridaforolimus plus exemestane alone; toxicity was significant, leading to discontinuation of further development for this indication[2][5].

Other names

ridaforolimus + dalotuzumab + exemestane